The European Medicines Agency’s advisory group CHMP has issued a negative opinion against approval of Daiichi Sankyo’s (OTCPK:DSKYF) Vanflyta
(quizartinib) for the treatment of adults with acute myeloid leukemia
(AML) citing the lack of evidence of enough of a survival benefit.
The company may request a re-examination of its application within 15 days of receiving the opinion.
https://seekingalpha.com/news/3506867-european-advisory-group-thumbs-daiichis-quizartinib
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.